介紹：FMC63抗體是一種針對人CD19的鼠單克隆抗體。CD19是目前CAR-T細(xì)胞治療領(lǐng)域中應(yīng)用最廣泛的靶點，大量研究表明，CD19是治療B細(xì)胞急性淋巴細(xì)胞白血?。˙-ALL）、慢性淋巴細(xì)胞白血?。–LL）和B細(xì)胞淋巴瘤等腫瘤有效且安全的靶點。而FMC63抗體的出現(xiàn)，使得CAR-T細(xì)胞治療更加精準(zhǔn)、安全。
名稱：Anti-CD19 (FMC63) CAR的特異性抗體蛋白
別名：FMC63，B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD19, CD19, Anti-FMC63
鏈接：https://www.antibodysystem.com/index/search?wd=FMC63
其他產(chǎn)品：
Anti-FMC63 scFv Monoclonal Antibody (SAA1996) (RAD10801)
Anti-Human CD19 scFv Antibody (FMC63) (RHD10803)
Anti-FMC63 scFv Monoclonal Antibody (SAA2162) (RAD10803)
Anti-Human CD19 Antibody (FMC63) (FHD10840)
形式：Liquid
純度：>95%-98%(SDS-PAGE & RP-HPLC)
Accession：P15391
優(yōu)勢：多種屬多標(biāo)簽，高穩(wěn)定性，高生物活性，高純度
用途范圍：僅用于科研
儲存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
AntibodySystem：
AntibodySystem是由法國ProteoGenix專家團(tuán)隊創(chuàng)立的科研試劑品牌，產(chǎn)品管線覆蓋各種病毒研究蛋白/抗體質(zhì)控品、Invivo功能性抗體，流式抗休、抗藥藥物靶點蛋白以及其他活性蛋白、PEG抗體，磷酸化抗體、抗DNA抗體、小分子抗體、RUO ELISA試劑盒、生物類似物。
佰樂博生物：佰樂博生物代理antibodysystem，ProteoGenix品牌，是亞洲區(qū)運營總代理商
產(chǎn)品購買聯(lián)系方式：027-65279366 /18162686757
郵箱：biolab-reagents@atagenix.com
QQ：2663991332
參考文獻(xiàn)：
Solving the mystery of the FMC63-CD19 affinity. PMID: 38155191
CD19 CAR antigen engagement mechanisms and affinity tuning. PMID: 36867678
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. PMID: 31959992
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line. PMID: 33271901
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. PMID: 33021872
A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. PMID: 35981465
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. PMID: 31477906
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study. PMID: 38066564
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. PMID: 32894185
Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells. PMID: 36453632
Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy. PMID: 37297020
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts. PMID: 36875091
Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation. PMID: 35222427
Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy. PMID: 33432627
Fully human CD19-specific chimeric antigen receptors for T-cell therapy. PMID: 28202953
Stealth transgenes enable CAR-T cells to evade host immune responses. PMID: 38724463
Preparation and characterization of a chimeric CD19 monoclonal antibody. PMID: 1725979
Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy. PMID: 33023981
Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells. PMID: 38659938
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. PMID: 38475814
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. PMID: 18676854
CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison. PMID: 38745250
Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. PMID: 9566763
Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells. PMID: 37206593
Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus. PMID: 35755944
Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design. PMID: 31702909
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells. PMID: 33632869
Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains. PMID: 35117999
Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients. PMID: 33843201
A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma. PMID: 35355931
